Asterivir AG

We are developing a broad spectrum antiviral platform that promises to produce medicines against a wide variety of viral diseases. We are pursuing influenza as our lead indication, but also have in vitro proof of concept data against a wide variety of viruses, including RSV, Sars-CoV-2, Dengue, Zika, Parainfluenza, etc. Much as penicillin revolutionised the treatment of bacterial infections 100 years ago, our ambition is to do the same for viral infections.